March 4, 2017 -- OrbiMed filed to raise $450 million for its third Asia-focused life science fund, which will bring its Asian assets under management to nearly $1 billion; Surefire Medical, a Colorado medical device maker, closed a $12.8 million D funding led by ORI Healthcare Fund of Hong Kong; Beijing CRO Pharmaron signed a definitive agreement to acquire a majority stake in Shin Nippon’s Clinical Pharmacology Center in Maryland; Singapore’s ASLAN Pharma formed an R&D collaboration with two Singapore medical research institutes to test ASLAN003 in hematologic cancers; HitGen of Chengdu and Houston out-licensed several novel molecules to Cancer Research UK for a new lung cancer target; the lead candidate for Hutchison China MediTech (Chi-Med), fruquintinib, met its endpoints in a pivotal Phase III China colorectal cancer trial; California’s Kite Pharma reported positive results from a US Phase III trial of its lead CAR-T immunotherapy (Fosun Pharma in-licensed China rights to the candidate in January); and CloudHealth Genomics of Shanghai announced a second genomics-based precision medicine test panel, ImmuneSeq Cancer, which profiles human response to immunotherapies in all cancer types.
